CD83 and breast cancer: The study using another marker of DC maturity, CD83, showed similar expression of mature DCs in tumor-negative SLNs and non-SLNs, but higher expression of co-stimulatory molecules in the latter, suggesting that immune response is suppressed before development of BC metastasis, but enhanced after the tumor is established in SLN [14].